We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

33 hedge funds and large institutions have $3.15M invested in AIM ImmunoTech in 2024 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

63% more capital invested

Capital invested by funds: $1.93M → $3.15M (+$1.22M)

18% more funds holding

Funds holding: 28 → 33 (+5)

Holders
33
Holders Change
+5
Holders Change %
+17.86%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
6
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$1.73M
2
TSS
Two Sigma Securities
New York
+$44K
3
Citadel Advisors
Citadel Advisors
Florida
+$41.6K
4
VF
Virtu Financial
New York
+$23.9K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$21K

Top Sellers

Rank Fund Capital Flow
1
DS
DRW Securities
Illinois
-$11.3K
2
BCM
Bridgeway Capital Management
Texas
-$8.49K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$7.93K
4
Verition Fund Management
Verition Fund Management
Connecticut
-$7.64K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$245
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$1.52M +$1.73M +40,821 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$741K – – –
BlackRock
3
BlackRock
New York
$260K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$150K +$21K +494 +14%
Renaissance Technologies
5
Renaissance Technologies
New York
$85.3K +$3.4K +80 +4%
State Street
6
State Street
Massachusetts
$64.5K – – –
Verition Fund Management
7
Verition Fund Management
Connecticut
$57K -$7.64K -180 -11%
TSS
8
Two Sigma Securities
New York
$46.6K +$44K +1,037 +485%
Citadel Advisors
9
Citadel Advisors
Florida
$36.5K +$41.6K +981 New
BCM
10
Bridgeway Capital Management
Texas
$33.1K -$8.49K -200 -18%
Morgan Stanley
11
Morgan Stanley
New York
$31.8K – – –
Northern Trust
12
Northern Trust
Illinois
$31.7K -$42 -1 -0.1%
VF
13
Virtu Financial
New York
$21K +$23.9K +563 New
SWM
14
SeaCrest Wealth Management
New York
$13.1K – – –
TRCT
15
Tower Research Capital (TRC)
New York
$9.97K +$3.65K +86 +47%
UBS Group
16
UBS Group
Switzerland
$7.95K +$9.04K +213 New
CAPTRUST Financial Advisors
17
CAPTRUST Financial Advisors
North Carolina
$7.45K – – –
FWM
18
ForthRight Wealth Management
Georgia
$7.45K – – –
XT
19
XTX Topco
Cayman Islands
$5.41K +$170 +4 +3%
CB
20
Community Bank
New York
$4.89K – – –
DBRC
21
D.B. Root & Company
Pennsylvania
$4.49K – – –
TCM
22
Traynor Capital Management
Pennsylvania
$4.39K – – –
CIBC Private Wealth Group
23
CIBC Private Wealth Group
Georgia
$1.84K +$2.12K +50 New
Wells Fargo
24
Wells Fargo
California
$427 +$127 +3 +38%
HI
25
Hoey Investments
Pennsylvania
$373 – – –
1
2

AIM Hedge Fund Activity: Q2 2024 in Review

33 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q2 2024, worth a combined $3.15M — up 63% from $1.93M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new AIM positions and 3 closed out — a net gain of 5 holders — while 6 added to existing stakes and 3 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $1.73M. The largest seller was DRW Securities, exiting entirely with an estimated $11.3K sold.

  • 33 institutional investors held AIM ImmunoTech (AIM) as of Q2 2024, up from 28 in Q1 2024.
  • Funds reported $3.15M of AIM ImmunoTech stock for Q2 2024, up 63% quarter-over-quarter.
  • 8 funds opened new AIM ImmunoTech positions in Q2 2024 and 3 closed out, a net change of +5 holders.
  • The largest AIM ImmunoTech buyer in Q2 2024 was Armistice Capital, an estimated $1.73M added.
  • The largest AIM ImmunoTech seller in Q2 2024 was DRW Securities, an estimated $11.3K sold.

Based on aggregated 13F filings for Q2 2024.